NGNE
Neurogene Inc.
$20.06
-$0.34(-1.67%)
50
Overall
60
Value
40
Tech
--
Quality
Market Cap
$330.86M
Volume
188.55K
52W Range
$6.88 - $37.27
Target Price
$52.40
Company Overview
| Mkt Cap | $330.86M | Price | $20.06 |
| Volume | 188.55K | Change | -1.67% |
| P/E Ratio | -4.4 | Open | $20.28 |
| Revenue | $925.0K | Prev Close | $20.40 |
| Net Income | $-75.1M | 52W Range | $6.88 - $37.27 |
| Div Yield | N/A | Target | $52.40 |
| Overall | 50 | Value | 60 |
| Quality | -- | Technical | 40 |
No chart data available
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
Latest News
Neurogene Inc. Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•6 days ago
Stifel Nicolaus Remains a Buy on Neurogene (NGNE)
TipRanks Auto-Generated Intelligence Newsdesk•10 days ago
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD)
Brian Anderson•17 days ago
Neurogene Begins Dosing in Rett Syndrome Trial
TipRanks Auto-Generated Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $20.06 | -1.7% | 188.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |